NCT02217501View on ClinicalTrials.gov

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

PHASE3CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 30, 2020

Study Completion Date

January 30, 2020

Conditions
Peripheral Arterial Disease
Interventions
DRUG

Clopidogrel

Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

DRUG

Acetylsalicylic acid (ASA)

Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months

Trial Locations (4)

52803

Midwest Cardiovascular Research Foundation, Davenport

75216

VA North Texas Health Care System, Dallas

75390

University of Texas Southwestern Medical Center, Dallas

80220

Denver VA Medical Center, Denver

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT02217501 - Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities | Biotech Hunter | Biotech Hunter